[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.166.22. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Download PDF
Figure 1.
Retinal changes associated with juvenile Paget disease. A, Peripapillary atrophy. B, Mottling of the retinal pigment epithelium. C, Angioid streaks.

Retinal changes associated with juvenile Paget disease. A, Peripapillary atrophy. B, Mottling of the retinal pigment epithelium. C, Angioid streaks.

Figure 2.
Coronal magnetic resonance image showing large bilateral intracavernous aneurysms of the internal carotid artery.

Coronal magnetic resonance image showing large bilateral intracavernous aneurysms of the internal carotid artery.

Figure 3.
Cumulative number of retinal abnormalities. Patient K is listed in Table 3.

Cumulative number of retinal abnormalities. Patient K is listed in Table 3.

Table 1. 
Clinical Details of Study Patients
Clinical Details of Study Patients
Table 2. 
Ophthalmic Features of Study Patients
Ophthalmic Features of Study Patients
Table 3. 
Patients in the Literature Having Juvenile Paget Disease With Ocular Features
Patients in the Literature Having Juvenile Paget Disease With Ocular Features
1.
Whyte  MPSinghellakis  PNPetersen  MBDavies  MTotty  WGMumm  S Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B “Balkan” mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. J Bone Miner Res 2007;22 (6) 938- 946
PubMedArticle
2.
Whyte  MPObrecht  SEFinnegan  PM  et al.  Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002;347 (3) 175- 184
PubMedArticle
3.
Chong  BHegde  MFawkner  M  et al. International Hyperphosphatasia Collaborative Group, Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 2003;18 (12) 2095- 2104
PubMedArticle
4.
Cundy  THegde  MNaot  D  et al.  A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002;11 (18) 2119- 2127
PubMedArticle
5.
Whyte  MP Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-κB signaling. Ann N Y Acad Sci 2006;1068143- 164
PubMedArticle
6.
Bakwin  HGolden  AFox  S Familial osteoctasia with macrocranium. Am J Roentgenol Radium Ther Nucl Med 1964;91609- 617
PubMed
7.
Iancu  TCAlmagor  GFriedman  EHardoff  RFront  D Chronic familial hyper- phosphatasemia. Radiology 1978;129 (3) 669- 676
PubMed
8.
Mitsudo  SM Chronic idiopathic hyperphosphatasia associated with pseudoxanthoma elasticum. J Bone Joint Surg Am 1971;53 (2) 303- 314
PubMed
9.
Sharif  KWDoig  WMKinsella  FP Visual impairment in a case of juvenile Paget's disease with pseudoxanthoma elasticum: an eleven-year follow-up. J Pediatr Ophthalmol Strabismus 1989;26 (6) 299- 302
PubMed
10.
Bakwin  HEiger  MS Fragile bones and macrocranium. J Pediatr 1956;49 (5) 558- 564
PubMedArticle
11.
Thompson  RC  JrGaull  GEHorwitz  SJSchenk  RK Hereditary hyperphosphatasia: studies of three siblings. Am J Med 1969;47 (2) 209- 219
PubMedArticle
12.
Schoppet  MPreissner  KTHofbauer  LC RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22 (4) 549- 553
PubMedArticle
13.
Luft  FC Pseudoxanthoma elasticum revealed. J Mol Med 2000;78 (5) 237- 238
PubMedArticle
14.
Lim  JIBressler  NMMarsh  MJBressler  SB Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 1993;116 (4) 414- 423
PubMed
15.
National Center for Biotechnology Information, Tumor necrosis factor receptor superfamily, member 11b (TNFRSF11B). http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?UGID=140556&TAXID=9606&SEARCH=osteoprotegerin. Accessed March 26, 2009
16.
Bucay  NSarosi  IDunstan  CR  et al.  Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12 (9) 1260- 1268
PubMedArticle
17.
Malyankar  UMScatena  MSuchland  KLYun  TJClark  EAGiachelli  CM Osteoprotegerin is an αvβ3-induced, NF-κB–dependent survival factor for endothelial cells. J Biol Chem 2000;275 (28) 20959- 20962
PubMedArticle
18.
Emery  JG McDonnell  PBurke  MB  et al.  Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273 (23) 14363- 14367
PubMedArticle
19.
Schoppet  MSattler  AMSchaefer  JRHofbauer  LC Osteoprotegerin (OPG) and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 2006;184 (2) 446- 447
PubMedArticle
20.
McGonigle  JSGiachelli  CScatena  M Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009;12 (1) 35- 46
PubMedArticle
21.
Silve  CGrosse  BTau  C  et al.  Response to parathyroid hormone and 1,25-dihydroxyvitamin D3 of bone-derived cells isolated from normal children and children with abnormalities in skeletal development. J Clin Endocrinol Metab 1986;62 (3) 583- 590
PubMedArticle
22.
Bennett  BJScatena  MKirk  EA  et al.  Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE−/− mice. Arterioscler Thromb Vasc Biol 2006;26 (9) 2117- 2124
PubMedArticle
23.
Allen  CAHart  BLTaylor  CLClericuzio  CL Bilateral cavernous internal carotid aneurysms in a child with juvenile Paget disease and osteoprotegerin deficiency. AJNR Am J Neuroradiol 2008;29 (1) 7- 8
PubMedArticle
24.
Schievink  WI Intracranial aneurysms. N Engl J Med 1997;336 (1) 28- 40
PubMedArticle
25.
Cundy  TWheadon  LKing  A Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res 2004;19 (5) 703- 711
PubMedArticle
26.
Tau  CMautalen  CCasco  CAlvarez  VRubinstein  M Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy. Bone 2004;35 (1) 210- 216
PubMedArticle
27.
Cundy  TDavidson  JRutland  MDStewart  CDePaoli  AM Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 2005;353 (9) 918- 923
PubMedArticle
28.
Romas  E Clinical applications of RANK-ligand inhibition. Intern Med J 2009;39 (2) 110- 116
PubMedArticle
29.
Puig  JGarcia-Arumi  JSalvador  FSararols  LCalatayud  MAlforja  S Subretinal neovascularization and hemorrhages in angioid streaks [in Spanish]. Arch Soc Esp Oftalmol 2001;76 (5) 309- 314
PubMed
30.
Lim  J I Iatrogenic choroidal neovascularization. Surv Ophthalmol 1999;44 (2) 95- 111
PubMedArticle
Clinical Sciences
June 2010

Ocular Manifestations of Juvenile Paget Disease

Author Affiliations

Author Affiliations: Departments of Ophthalmology, New Zealand National Eye Centre (Drs Kerr and Vincent) and Medicine (Dr Cundy), Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Endocrinología, Hospital de Niños (Dr Cassinelli), and Endocrinología, Hospital de Pediatría Garrahan (Dr Tau), Buenos Aires, Argentina; Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis (Dr DiMeglio); and Department of Pediatrics, Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey (Dr Tüysüz).

Arch Ophthalmol. 2010;128(6):698-703. doi:10.1001/archophthalmol.2010.76
Abstract

Objectives  To determine the prevalence and spectrum of retinal changes in juvenile Paget disease.

Methods  Observational case series and literature review with analysis. Patients with clinical and molecular evidence of juvenile Paget disease were recruited by members of the International Hyperphosphatasia Collaborative Group. Participants underwent ophthalmic examinations consisting of at least best-corrected Snellen visual acuity and dilated fundal examination or color fundus photography. A MEDLINE literature search was performed, and all identified case reports were reviewed for information regarding ocular phenotype.

Results  Fourteen eyes from 7 patients were examined. The mean (SD) patient age was 22 (8) years, and 4 patients were female. Retinal abnormalities were evident in 12 of 14 eyes and were reported among an additional 12 patients in the literature. Retinal abnormalities included mottling of the retinal pigment epithelium, peripapillary atrophy, angioid streaks, and choroidal neovascularization. Cumulative number of retinal abnormalities was strongly associated with increasing age.

Conclusions  Juvenile Paget disease is associated with progressive retinopathy characterized by the development of angioid streaks, which may be complicated by choroidal neovascularization, the predominant cause of visual loss. Osteoprotegerin or its signaling pathway may have a role in calcification of Bruch membrane and in the pathogenesis of angioid streaks. Retinopathy in patients with juvenile Paget disease may be a sign of a more generalized vascular disorder.

Juvenile Paget disease, or idiopathic hyperphosphatasia, is a rare recessively inherited disorder characterized by greatly accelerated bone turnover throughout the skeleton. Since the condition was first described in 1956, approximately 50 cases have been reported worldwide.1 Affected individuals are healthy at birth but manifest progressive long-bone deformity, kyphoscoliosis, growth impairment, and fractures in infancy or early childhood.2 The skull is also involved, and patients typically have massive thickening of the calvaria and sensorineural hearing loss. Life expectancy is reduced largely because of severe restrictive lung disease secondary to chest wall deformity. Bony changes are the consequence of increased activity of osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). Juvenile Paget disease results from deletions or loss-of-function mutations in the TNFRSF11B gene (OMIM *602643), which encodes the protein osteoprotegerin, a key regulator of bone turnover.35

Because skeletal features predominate, other manifestations of the disorder have received little attention. Retinal changes and blindness have been described in some patients,1,69 but the literature regarding ocular manifestations of juvenile Paget disease is limited, and most case reports do not indicate whether the eyes were examined. The objectives of this study were to determine the prevalence and natural history of retinopathy in juvenile Paget disease and to characterize the spectrum of retinal changes.

METHODS

Patients with juvenile Paget disease were recruited by members of the International Hyperphosphatasia Collaborative Group in Argentina, Turkey, the United States, and New Zealand. The sole inclusion criterion was clinical and molecular diagnosis of juvenile Paget disease. There were no exclusion criteria. The age at diagnosis, presence or absence of visual symptoms, duration of visual symptoms, extraocular phenotypic features, and a detailed family history were obtained for each patient. Ophthalmic examinations consisted of at least best-corrected Snellen visual acuity and dilated binocular indirect ophthalmoscopy by an ophthalmologist (N.M.K. and A.L.V.) or color fundus photography through pharmacologically dilated pupils. At a minimum, fields were required from the posterior pole and the peripheral retina. Because of skeletal manifestations of this disorder, specifically limited cervical flexion and extension, standardized photography was not practical. Where possible, patients underwent full examination by an ophthalmologist consisting of best-corrected Snellen visual acuity, visual fields to confrontation, brightness sense, red perception, pseudoisochromatic color Ishihara plates, pupillary assessment, slitlamp biomicroscopy, Goldmann applanation tonometry, and dilated funduscopy. All patients provided peripheral blood samples for genomic DNA analysis as reported previously.3 Informed consent was obtained from all participants, and the study complied with the tenets of the Declaration of Helsinki.

A literature search was performed using MEDLINE (January 1, 1950, to present) for the terms juvenile Paget* disease, osteoprotegerin deficiency, and idiopathic hyperphosphatasia. All identified case reports were reviewed for information regarding the ocular phenotype.

RESULTS

Seven patients with juvenile Paget disease were identified, and all but 1 had retinal abnormalities. Three patients were siblings (patients 3, 6, and 7); clinical details of all study patients are summarized in Table 1. The mean age at presentation was 5 years; most patients manifested difficulty in walking and long-bone deformities with or without fractures. The mean (SD) patient age at the time of study was 22 (8) years (age range, 13-31 years). All patients had sensorineural hearing loss and biochemical evidence of increased bone turnover. All were homozygous for probable loss-of-function mutations in TNFRSF11B. Details of the skeletal and genetic findings in 6 of these patients have been published previously.3

The ophthalmic findings are summarized in Table 2. All patients had best-corrected visual acuity of 20/30 Snellen or better. Results of optic nerve function clinical tests (visual fields to confrontation, brightness sense, red perception, pseudoisochromatic color Ishihara plates, and pupillary assessment) and slitlamp examinations of the anterior segment were normal in patients 3, 6, and 7. Slitlamp examination could not be performed in patients 1 and 2.

All patients underwent dilated fundal examination by an ophthalmologist or color fundus photography of the posterior pole and peripheral retina through pharmacologically dilated pupils. The fundus was normal in only 1 patient examined. Optic nerve pallor was evident in 4 patients, and 4 patients had peripapillary atrophy. Five patients had mottling of the retinal pigment epithelium, and an equal number had angioid streaks. These changes are shown in Figure 1. In patient 7 (Table 2), angioid streaks were complicated by peripapillary choroidal neovascularization. Shortly after undergoing retinal examination as part of this study, patient 4 was seen with signs of cavernous sinus syndrome, including bilateral chemosis and convergent strabismus secondary to bilateral sixth nerve palsies. Magnetic resonance imaging revealed large bilateral intracavernous aneurysms of the internal carotid artery (Figure 2).

We identified 40 case reports of juvenile Paget disease describing 55 patients in the literature. Ocular manifestations were described in 12 patients, including serial follow-up in 3 patients (Table 3).1,611 Angioid streaks were the most common ocular abnormality. They were found in almost all patients by the end of the second decade of life and seemed to be a precursor to the development of choroidal neovascularization, which occurred in more than half of those with angioid streaks. Subsequent involvement of the macula by disciform scarring was the predominant cause of visual loss. Two patients with long-term serial follow-up developed blindness due to choroidal neovascularization and disciform scarring.1,8

The nonspecific finding of mottling of the retinal pigment epithelium was observed less frequently and was more common in older patients. Peripapillary atrophy and optic nerve pallor were less frequent observations across all age groups. Electrophysiologic studies were undertaken in 4 patients, and all results were abnormal, showing diminished photoreceptor function. There was a striking correlation between cumulative number of retinal abnormalities and increasing age (Figure 3).

COMMENT

To our knowledge, this is the largest systematic study of ophthalmic manifestations of juvenile Paget disease reported to date. It confirms that juvenile Paget disease is associated with distinctive retinopathy that is detectable in most patients by the end of the second decade of life. Cumulative number of retinal abnormalities is strongly associated with older age, suggesting that this is a progressive disorder. The earliest changes seem to be optic nerve pallor and mottling of the retinal pigment epithelium. This is followed by the development of angioid streaks, choroidal neovascularization, and ultimately disciform scarring and visual loss. Among patients in whom electrophysiologic studies were undertaken, this seems to correlate with altered retinal function. Two published case reports1,9 of patients studied serially provide evidence that severe visual loss can occur. Both patients had mild skeletal phenotypes. Because they have the longest life expectancy, such patients may paradoxically be at greatest risk of visual loss.

Juvenile Paget disease results from deletions of or loss-of-function mutations in TNFRSF11B, which encodes osteoprotegerin. Osteoprotegerin is a soluble homodimeric glycoprotein, secreted by osteoblasts and osteoblast precursors, that has an important role in regulating bone turnover. Osteoprotegerin is a decoy receptor for receptor activator of nuclear factor-κB ligand (RANKL), which dampens the stimulus to bone resorption; therefore, osteoprotegerin deficiency is characterized by unrestrained bone remodeling activity.12

Patients with juvenile Paget disease have greatly expanded skull bones, so it is possible that the optic nerve pallor and atrophy we observed could result from bony compression of the optic nerve at the orbital apex. Mottling of the retinal pigment epithelium seems to be an early sign and may represent changes in underlying Bruch membrane. Angioid streaks were a common finding. These are linear gray or dark red lesions that typically extend radially from the optic disc and run beneath the retinal vessels.13 They are seen in a wide variety of systemic conditions and are of significance because they may be complicated by choroidal neovascularization in up to 86% of cases.14 Although recognized as breaks or dehiscence in a thickened, calcified, and abnormally brittle Bruch membrane, their exact pathogenesis remains unknown. Therefore, osteoprotegerin deficiency may provide new insights about pathogenesis of angioid streaks. Osteoprotegerin is expressed in many tissues, including the eye and vascular endothelium.15 Animal investigations have shown that osteoprotegerin-deficient mice develop calcification of the internal elastic lamina of the aorta and renal arteries, suggesting that osteoprotegerin acts as an inhibitor of calcification of elastic fibers.16 Angioid streaks have not been described in the analogous bone condition of familial expansile osteolysis, which results from constitutive activation of RANK due to tandem duplications within its TNFRSF11A gene.5 This suggests that osteoprotegerin deficiency causes angioid streaks through a system independent of RANK activation. Osteoprotegerin may prevent vascular calcification by inhibiting apoptosis of endothelial cells caused by tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL).17 Indeed, it has been shown that osteoprotegerin protects endothelial cells from apoptosis induced by serum withdrawal and nuclear factor-κB inactivation.17 Therefore, osteoprotegerin deficiency may lead to angioid streaks through loss of inhibition of calcification in the elastin-rich middle elastic layer of Bruch membrane, with subsequent formation of cracks.18,19 Whether susceptibility of the choriocapillaris endothelium to apoptosis20 contributes to this process requires further investigation.

Angioid streaks may be a marker or indicator of calcification in the systemic vasculature. Association between juvenile Paget disease and vascular calcification has been clinically observed. Mitsudo8 reported that calcium deposits were found in the intima of all muscular arteries at the time of autopsy in a 17-year-old boy with juvenile Paget disease who died of intracerebral hemorrhage. Furthermore, a temporal artery biopsy specimen from a 6-year-old boy with the disease revealed calcification of the internal elastic lamina.21 These findings are in keeping with results of animal investigations showing that osteoprotegerin-deficient mice develop early arterial calcification.22 In our study, a patient investigated for signs of cavernous sinus syndrome was found to have intracavernous internal carotid artery aneurysms that were identical to those recently described by Allen et al23 in an 11-year-old boy with a severe form of juvenile Paget disease due to complete deletion of TNFRSF11B. Compared with extracranial arteries, intracranial arteries have an attenuated tunica media and lack an external elastic lamina, rendering them vulnerable to aneurysm formation.24

Results of studies25,26 indicate that the skeletal phenotype of juvenile Paget disease can be ameliorated with intensive bisphosphonate treatment to inhibit bone turnover. However, neither systemic therapy with antireportive agents1,2 nor drugs specifically targeting the RANKL-osteoprotegerin-RANK system27 seem effective in modifying the ocular phenotype. Furthermore, response to choroidal neovascularization photodynamic therapy has been disappointing,9 and there are no published reports of treatment with intravitreal anti-VEGF agents. Newer agents such as denosumab that mimic the effects of osteoprotegerin28 may influence the ocular phenotype; however, their efficacy remains to be proven. Given the rarity of this disease, it is unlikely there will ever be an “evidence-based” treatment.

Based on our findings, we recommend that patients with juvenile Paget disease be examined by an ophthalmologist at diagnosis and then on a regular basis according to the severity of ocular involvement. Patients should be warned about the risk of visual loss and should be advised to immediately report any changes in vision. Furthermore, patients with angioid streaks should be informed of the possibility of subretinal hemorrhage after even minor ocular trauma.29 The regular use of a macular Amsler grid to screen for metamorphopsia, which may be the first sign of choroidal neovascularization, may be beneficial. Prophylactic laser treatment of angioid streaks is discouraged by some authorities because of the risk of choroidal neovascular membrane formation.30

We conclude that juvenile Paget disease is associated with progressive retinopathy characterized by optic nerve pallor, mottling of the retinal pigment epithelium, and subsequent development of angioid streaks. The latter may be complicated by choroidal neovascularization, the predominant mechanism of visual loss. Retinal changes are evident by the end of the second decade of life, and the severity of retinopathy increases with age. Paradoxically, patients with a mild skeletal phenotype may be at greatest risk of ocular complications. With early use of potent bisphosphonates, amelioration of the skeletal disease could lengthen the lifespan of affected patients, increasing the risk of retinal disease development. Retinopathy associated with juvenile Paget disease seems to be part of a more generalized vascular disorder, suggesting that osteoprotegerin or its signaling pathway has an important role in inhibition of vascular calcification.

Back to top
Article Information

Correspondence: Andrea L. Vincent, MBChB, Department of Ophthalmology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand (a.vincent@auckland.ac.nz).

Submitted for Publication: June 29, 2009; final revision received November 3, 2009; accepted November 5, 2009.

Financial Disclosure: None reported.

References
1.
Whyte  MPSinghellakis  PNPetersen  MBDavies  MTotty  WGMumm  S Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B “Balkan” mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. J Bone Miner Res 2007;22 (6) 938- 946
PubMedArticle
2.
Whyte  MPObrecht  SEFinnegan  PM  et al.  Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002;347 (3) 175- 184
PubMedArticle
3.
Chong  BHegde  MFawkner  M  et al. International Hyperphosphatasia Collaborative Group, Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 2003;18 (12) 2095- 2104
PubMedArticle
4.
Cundy  THegde  MNaot  D  et al.  A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002;11 (18) 2119- 2127
PubMedArticle
5.
Whyte  MP Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-κB signaling. Ann N Y Acad Sci 2006;1068143- 164
PubMedArticle
6.
Bakwin  HGolden  AFox  S Familial osteoctasia with macrocranium. Am J Roentgenol Radium Ther Nucl Med 1964;91609- 617
PubMed
7.
Iancu  TCAlmagor  GFriedman  EHardoff  RFront  D Chronic familial hyper- phosphatasemia. Radiology 1978;129 (3) 669- 676
PubMed
8.
Mitsudo  SM Chronic idiopathic hyperphosphatasia associated with pseudoxanthoma elasticum. J Bone Joint Surg Am 1971;53 (2) 303- 314
PubMed
9.
Sharif  KWDoig  WMKinsella  FP Visual impairment in a case of juvenile Paget's disease with pseudoxanthoma elasticum: an eleven-year follow-up. J Pediatr Ophthalmol Strabismus 1989;26 (6) 299- 302
PubMed
10.
Bakwin  HEiger  MS Fragile bones and macrocranium. J Pediatr 1956;49 (5) 558- 564
PubMedArticle
11.
Thompson  RC  JrGaull  GEHorwitz  SJSchenk  RK Hereditary hyperphosphatasia: studies of three siblings. Am J Med 1969;47 (2) 209- 219
PubMedArticle
12.
Schoppet  MPreissner  KTHofbauer  LC RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22 (4) 549- 553
PubMedArticle
13.
Luft  FC Pseudoxanthoma elasticum revealed. J Mol Med 2000;78 (5) 237- 238
PubMedArticle
14.
Lim  JIBressler  NMMarsh  MJBressler  SB Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 1993;116 (4) 414- 423
PubMed
15.
National Center for Biotechnology Information, Tumor necrosis factor receptor superfamily, member 11b (TNFRSF11B). http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?UGID=140556&TAXID=9606&SEARCH=osteoprotegerin. Accessed March 26, 2009
16.
Bucay  NSarosi  IDunstan  CR  et al.  Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12 (9) 1260- 1268
PubMedArticle
17.
Malyankar  UMScatena  MSuchland  KLYun  TJClark  EAGiachelli  CM Osteoprotegerin is an αvβ3-induced, NF-κB–dependent survival factor for endothelial cells. J Biol Chem 2000;275 (28) 20959- 20962
PubMedArticle
18.
Emery  JG McDonnell  PBurke  MB  et al.  Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273 (23) 14363- 14367
PubMedArticle
19.
Schoppet  MSattler  AMSchaefer  JRHofbauer  LC Osteoprotegerin (OPG) and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 2006;184 (2) 446- 447
PubMedArticle
20.
McGonigle  JSGiachelli  CScatena  M Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009;12 (1) 35- 46
PubMedArticle
21.
Silve  CGrosse  BTau  C  et al.  Response to parathyroid hormone and 1,25-dihydroxyvitamin D3 of bone-derived cells isolated from normal children and children with abnormalities in skeletal development. J Clin Endocrinol Metab 1986;62 (3) 583- 590
PubMedArticle
22.
Bennett  BJScatena  MKirk  EA  et al.  Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE−/− mice. Arterioscler Thromb Vasc Biol 2006;26 (9) 2117- 2124
PubMedArticle
23.
Allen  CAHart  BLTaylor  CLClericuzio  CL Bilateral cavernous internal carotid aneurysms in a child with juvenile Paget disease and osteoprotegerin deficiency. AJNR Am J Neuroradiol 2008;29 (1) 7- 8
PubMedArticle
24.
Schievink  WI Intracranial aneurysms. N Engl J Med 1997;336 (1) 28- 40
PubMedArticle
25.
Cundy  TWheadon  LKing  A Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res 2004;19 (5) 703- 711
PubMedArticle
26.
Tau  CMautalen  CCasco  CAlvarez  VRubinstein  M Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy. Bone 2004;35 (1) 210- 216
PubMedArticle
27.
Cundy  TDavidson  JRutland  MDStewart  CDePaoli  AM Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 2005;353 (9) 918- 923
PubMedArticle
28.
Romas  E Clinical applications of RANK-ligand inhibition. Intern Med J 2009;39 (2) 110- 116
PubMedArticle
29.
Puig  JGarcia-Arumi  JSalvador  FSararols  LCalatayud  MAlforja  S Subretinal neovascularization and hemorrhages in angioid streaks [in Spanish]. Arch Soc Esp Oftalmol 2001;76 (5) 309- 314
PubMed
30.
Lim  J I Iatrogenic choroidal neovascularization. Surv Ophthalmol 1999;44 (2) 95- 111
PubMedArticle
×